Mukwonago, Wisconsin - Sherrie Palm, author of the award-winning book "Pelvic Organ Prolapse: The Silent Epidemic", and the founder/executive director of APOPS, Association for Pelvic Organ Prolapse Support, a U.S.-based 501c3 nonprofit with international arms, is requesting contributions of any size to fund STIGMA*STRIDE Pennies for POP campaign.

Washington, DC - Forty states have enacted laws prohibiting the sale of electronic nicotine delivery systems (ENDS), including e-cigarettes, to minors, but 10 states and the District of Columbia still permit such sales, according to a report published by the Centers for Disease Control and Prevention in today’s Morbidity and Mortality Weekly Report (MMWR).

Washington, DC - The U.S. Food and Drug Administration today approved MP Diagnostics HTLV Blot 2.4, the first FDA-licensed supplemental test for Human T-cell Lymphotropic Virus-I/II (HTLV-I/II). This test is intended for use as an additional, more specific test for human serum or plasma specimens that have previously tested positive on an FDA-licensed HTLV-I/II blood donor screening test. The MP Diagnostics HTLV Blot 2.4 is a qualitative enzyme immunoassay test intended to confirm infection with HTLV and to differentiate between HTLV-I and HTLV-II.

Pittsburgh, Pennsylvania - Treating the potentially blinding haze of a scar on the cornea might be as straightforward as growing stem cells from a tiny biopsy of the patient’s undamaged eye and then placing them on the injury site, according to mouse model experiments conducted by researchers at the University of Pittsburgh School of Medicine. The findings, published today in Science Translational Medicine, could one day rescue vision for millions of people worldwide and decrease the need for corneal transplants.

Washington, DC - The 2012 Tips From Former Smokers campaign spent only $480 per smoker who quit and $393 per year of life saved, according to an analysis by the Centers for Disease Control and Prevention. The results of the study were published today in the American Journal of Preventive Medicine.

Washington, DC - The U.S. Food and Drug Administration today approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the prevention of certain diseases caused by nine types of Human Papillomavirus (HPV). Covering nine HPV types, five more HPV types than Gardasil (previously approved by the FDA), Gardasil 9 has the potential to prevent approximately 90 percent of cervical, vulvar, vaginal and anal cancers.